Phathom Pharmaceuticals, Inc.
PHATHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePhathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. With a market capitalization of $464.4M, it sits in small-cap territory. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
Market Cap
$464.4M
Beta
0.50
P/E (TTM)
—
P/E (Fwd)
5.34
EPS (TTM)
$-1.26
EPS (Fwd)
$1.08
ROE
—
ROA
-8.8%
Cash
$182.5M
Total Debt
$552.0M
Free CF
-$32.6M
52W Change
-57.6%
Annual Financials
Cash vs Debt
Where PHAT stands vs its 150-day and 200-day moving averages
As of the October 13, 2026 close, PHAT finished 30.44% below its 150-day moving average ($10.25) and 35.82% below its 200-day moving average ($11.11). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PHAT overbought or oversold?
At the October 13, 2026 close, PHAT's RSI(14) was 37.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $182.5M in cash, though total debt stands at $552.0M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$32.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet.
PHAT's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Phathom Pharmaceuticals, Inc. and its sector.